Найду. Беспокойный мозг (2021). Ума Найду раскрывает множество секретов, в каждой главе рассказывая о вредных и полезных элементах повседневных продуктов, которые усугубляют наше психоэмоциональное состояние
 Скачать 7.83 Mb.
|
|
ГЛАВА 9. Биполярное расстройство и шизофрения 1. Insel T. Post by Former NIMH Director Thomas Insel: Transforming Diagnosis. National Institute of Mental Health website. April 29, 2013. https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2013/ transforming-diagnosis.shtml. Accessed October 4, 2019. 2. Lynham AJ, Hubbard L, Tansey KE, et al. Examining cognition across the bipolar/schizophrenia diagnostic spectrum. Journal of Psychiatry and Neuroscience. 2018; 43(4): 245–253. doi: 10.1503/jpn.170076. 3. Leboyer M, Soreca I, Scott J, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? Journal of Affective Disorders. 2012; 141(1): 1–10. doi: 10.1016/ j.jad.2011.12.049. 4. Tseng P-T, Zeng B-S, Chen Y-W, Wu M-K, Wu C-K, Lin P-Y. A meta- analysis and systematic review of the comorbidity between irritable bowel syndrome and bipolar disorder. Medicine. 2016; 95(33): e4617. doi: 10.1097/md.0000000000004617. 5. Legendre T, Boudebesse C, Henry C, Etain B. Antibiomania: penser au syndrome maniaque secondaire a une antibiotherapie. L’Encйphale. 2017; 43(2): 183–186. doi: 10.1016/ j.encep.2015.06.008. 6. Gao J. Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome. Experimental and Therapeutic Medicine. 2013; 6(1): 93–96.doi: 10.3892/etm.2013.1101. Ума Найду 420 7. Liu L, Zhu G. Gut-brain axis and mood disorder. Frontiers in Psychiatry. 2018; 9. doi: 10.3389/fpsyt.2018.00223. 8. Evans SJ, Bassis CM, Hein R, et al. The gut microbiome composition associates with bipolar disorder and illness severity. Journal of Psychiatric Research. 2017; 87: 23–29. doi: 10.1016/ j.jpsychires.2016.12.007. 9. Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: microbial endocrinology in the design and use of probiotics. BioEssays. 2011; 33(8): 574–581. doi: 10.1002/ bies.201100024; Barrett E, Ross RP, O’Toole PW, Fitzgerald GF, Stanton C. γ-Aminobutyric acid production by culturable bacteria from the human intestine. Journal of Applied Microbiology. 2012; 113(2): 411–417. doi: 10.1111/j.1365-2672.2012.05344.x. 10. Machado-Vieira R, Manji HK, Zarate Jr CA. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disorders. 2009; 11: 92–109. doi:10.1111/j.1399-5618.2009.00714.x. 11. Jacka FN, Pasco JA, Mykletun A, et al. Diet quality in bipolar disorder in a population-based sample of women. Journal of Affective Disorders. 2011; 129(1–3): 332–337.doi: 10.1016/ j.jad.2010.09.004. 12. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. Journal of Clinical Psychiatry. 2001; 62(6): 486–491. doi: 10.4088/jcp.v62n0614. 13. Noguchi R, Hiraoka M, Watanabe Y, Kagawa Y. Relationship between dietary patterns and depressive symptoms: difference by gender, and unipolar and bipolar depression. Journal of Nutritional Science and Vitaminology. 2013; 59(2): 115–122. doi: 10.3177/ jnsv.59.115; Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. American Journal of Psychiatry. 2003; 160(12): 2222–2227. doi: 10.1176/appi. ajp.160.12.2222. 14. Łojko D, Stelmach-Mardas M, Suwalska A. Diet quality and eating patterns in euthymic bipolar patients. European Review for Medical and Pharmacological Sciences. 2019; 23(3): 1221–1238. doi: 10.26355/ eurrev_201902_17016; McElroy SL, Crow S, Biernacka JM, et al. Clinical phenotype of bipolar disorder with comorbid binge eating disorder. Journal of Affective Disorders. 2013; 150(3): 981–986. doi:10.1016/j.jad.2013.05.024. 15. Melo MCA, de Oliveira Ribeiro M, de Araújo CFC, de Mesquita LMF, de Bruin PFC, de Bruin VMS. Night eating in bipolar disorder. Sleep Medicine. 2018 Aug; 48: 49–52. doi: 10.1016/j.sleep.2018.03.031. 16. Bauer IE, Gálvez JF, Hamilton JE, et al. Lifestyle interventions targeting dietary habits and exercise in bipolar disorder: a systematic review. Journal of Psychiatric Research. 2016; 74: 1–7. doi: 10.1016/j. jpsychires.2015.12.006; Frank E, Wallace ML, Hall M, et al. An integrated risk reduction intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial. Bipolar Disorders. 2014; 17(4): 424–437. doi: 10.1111 /bdi.12283. 17. Brietzke E, Mansur RB, Subramaniapillai M, et al. Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments. Список литературы 421 Neuroscience and Biobehavioral Reviews. 2018; 94: 11–16. doi: 10.1016/j.neubiorev. 2018.07.020; Phelps JR, Siemers SV, El-Mallakh RS. The ketogenic diet for type II bipolar disorder. Neurocase. 2013; 19(5): 423–426. doi: 10.1080/135 54794.2012.690421. 18. Campbell IH, Campbell H. Ketosis and bipolar disorder: controlled analytic study of online reports. BJPsych Open. 2019; 5(4). doi: 10.1192/ bjo.2019.49. 19. Brietzke E, Mansur RB, Subramaniapillai M, et al. Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments. Neuroscience and Biobehavioral Reviews. 2018; 94: 11–16. doi: 10.1016/j. neubiorev.2018.07.020. 20. Kim Y, Santos R, Gage FH, Marchetto MC. Molecular mechanisms of bipolar disorder: progress made and future challenges. Frontiers in Cellular Neuroscience. 2017; 11. doi: 10.3389 /fncel.2017.00030. 21. Malinauskas BM, Aeby VG, Overton RF, Carpenter-Aeby T, Barber- Heidal K. A survey of energy drink consumption patterns among college students. Nutrition Journal. 2007; 6(1). doi: 10.1186/1475-2891-6-35. 22. Rizkallah É, Bélanger M, Stavro K, et al. Could the use of energy drinks induce manic or depressive relapse among abstinent substance use disorder patients with comorbid bipolar spectrum disorder? Bipolar Disorders. 2011; 13(5–6): 578–580. doi: 10.1111/j.1399-5618. 2011.00951.x; Kiselev BM, Shebak SS, Milam TR. Manic episode following ingestion of caffeine pills. Primary Care Companion for CNS Disorders. June 2015. doi: 10.4088/pcc.14l01764. 23. Winston AP, Hardwick E, Jaberi N. Neuropsychiatric effects of caffeine. Advances in Psychiatric Treatment. 2005; 11(6): 432–439. doi: 10.1192/ apt.11.6.432; Lorist MM, Tops M. Caffeine, fatigue, and cognition. Brain and Cognition. 2003;53(1):82–94. 24. Kiselev BM, Shebak SS, Milam TR. Manic episode following ingestion of caffeine pills. Primary Care Companion for CNS Disorders. June 2015. doi: 10.4088/pcc.14l01764. 25. Johannessen L, Strudsholm U, Foldager L, Munk-Jørgensen P. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. Journal of Affective Disorders. 2006; 95(1–3): 13–17. doi: 10.1016/j. jad.2006.03.027; Rihmer Z, Gonda X, Dome P. Is mania the hypertension of the mood? Discussion of a hypothesis. Current Neuropharmacology. 2017; 15(3): 424–433. doi: 10.2174/1570159x14666160902145635. 26. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Markers of gluten sensitivity in acute mania: a longitudinal study. Psychiatry Research. 2012; 196(1): 68–71. doi: 10.1016/j. psychres.2011.11.007. 27. Severance EG, Gressitt KL, Yang S, et al. Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disorders. 2013; 16(3): 230–240. doi: 10.1111/bdi.12159. 28. Goldstein BI, Velyvis VP, Parikh SV. The association between moderate alcohol use and illness severity in bipolar disorder. Journal of Clinical Psychiatry. 2006;67(1):102–6. doi: 10.4088/jcp.v67n0114. Ума Найду 422 29. Jaffee WB, Griffin ML, Gallop R, et al. Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders. Journal of Clinical Psychiatry. 2008; 70(2): 171–176. doi: 10.4088/jcp.08m04011; Manwani SG, Szilagyi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. Journal of Clinical Psychiatry. 007; 68(8): 1172–1176. doi: 10.4088/jcp.v68n0802. 30. van Zaane J, van den Brink W, Draisma S, Smit JH, Nolen WA. The effect of moderate and excessive alcohol use on the course and outcome of patients with bipolar disorders. Journal of Clinical Psychiatry. 2010; 71(7): 885–893. doi:10.4088/jcp.09m05079gry; Ostacher MJ, Perlis RH, Nierenberg AA, et al. Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry. 2010; 167(3): 289–97. doi: 10.1176/appi.ajp.2009.09020299. 31. Bailey DG, Dresser G, Arnold JMO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? Canadian Medical Association Journal. 2012; 185(4): 309–316. doi: 10.1503/cmaj.120951. 32. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. American Journal of Psychiatry. 2003; 160 (12): 2222–2227. doi:10.1176/ appi.ajp.160.12.2222. 33. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder. Journal of Clinical Psychiatry. 2011; 73(1): 81–86. doi: 10.4088/ jcp.10r06710. 34. Bauer IE, Green C, Colpo GD, et al. A double-blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. Journal of Clinical Psychiatry. 2018; 80(1). doi: 10.4088/jcp.18m12200. 35. Berk M, Turner A, Malhi GS, et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Medicine. 2019; 17(1). doi: 10.1186/s12916-019-1257-1. 36. Nierenberg AA, Montana R, Kinrys G, Deckersbach T, Dufour S, Baek JH. L-methylfolate for bipolar I depressive episodes: an open trial proof-of-concept registry. Journal of Affective Disorders. 2017; 207: 429–433. doi: 10.1016/j.jad.2016.09.053. 37. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. Journal of Affective Disorders. 1986; 10(1): 9–13. doi: 10.1016/0165-0327(86)90043-1. 38. Sharpley AL, Hockney R, McPeake L, Geddes JR, Cowen PJ. Folic acid supplementation for prevention of mood disorders in young people at familial risk: a randomised, double blind, placebo controlled trial. Journal of Affective Disorders. 2014; 167: 306–311. doi: 10.1016/j. jad.2014.06.011. 39. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M. Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized Список литературы 423 controlled trial. Acta Psychiatrica Scandinavica. 2009; 120(6): 441–445. doi: 10.1111/j.1600-0447.2009.01368.x. 40. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S. Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Research. 1999; 89(3): 239–246. doi: 10.1016/s0165-1781(99)00107-9. 41. Chouinard G, Beauclair L, Geiser R, Etienne P. A pilot study of magnesium aspartate hydrochloride (Magnesiocard®) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1990; 14(2): 171–180. doi: 10.1016/0278-5846(90)90099-3. 42. Siwek M, Sowa-Kućma M, Styczeń K, et al. Decreased serum zinc concentration during depressive episode in patients with bipolar disorder. Journal of Affective Disorders. 2016; 190: 272–277. doi: 10.1016/j.jad.2015.10.026. 43. Millett CE, Mukherjee D, Reider A, et al. Peripheral zinc and neopterin concentrations are associated with mood severity in bipolar disorder in a gender-specific manner. Psychiatry Research. 2017; 255: 52–58. doi: 10.1016/j.psychres.2017.05.022. 44. Zheng P, Zeng B, Liu M, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Science Advances. 2019; 5(2): eaau8317. 45. Severance EG, Prandovszky E, Castiglione J, Yolken RH. Gastroenterology issues in schizophrenia: why the gut matters. Current Psychiatry Reports. 2015; 17(5). doi: 10.1007/s11920-015-0574-0. 46. Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Annals of the New York Academy of Sciences. 2012;1262(1):56–66. doi:10.1111/ j.1749-6632.2012.06638.x; Caso J, Balanzá-Martínez V, Palomo T, García-Bueno B. The microbiota and gut-brain axis: contributions to the immunopathogenesis of schizophrenia. Current Pharmaceutical Design. 2016; 22(40): 6122–6133. doi: 10.2174/ 1381612822666160906160911. 47. Dickerson F, Severance E, Yolken R. The microbiome, immunity, and schizophrenia and bipolar disorder. Brain, Behavior, and Immunity. 2017; 62: 46–52. doi: 10.1016/j.bbi.2016.12.010. 48. Tsuruga K, Sugawara N, Sato Y, et al. Dietary patterns and schizophrenia: a comparison with healthy controls. Neuropsychiatric Disease and Treatment. April 2015: 1115. doi: 10.2147/ ndt.s74760. 49. Yang X, Sun L, Zhao A, et al. Serum fatty acid patterns in patients with schizophrenia: a targeted metabonomics study. Translational Psychiatry. 2017; 7(7): e1176–e1176. doi: 10.1038/ tp.2017.152. 50. Dohan FC. Cereals and schizophrenia data and hypothesis. Acta Psychiatrica Scandinavica. 1966; 42(2): 125–152.doi: 10.1111/j.1600- 0447.1966.tb01920.x. 51. Čiháková D, Eaton WW, Talor MV, et al. Gliadin-related antibodies in schizophrenia. Schizophrenia Research. 2018; 195: 585–586. doi: 10.1016/j.schres.2017.08.051; Kelly DL, Demyanovich HK, Rodriguez Ума Найду 424 KM, et al. Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study. Journal of Psychiatry and Neuroscience. 2019; 44(4): 269–276. doi: 10.1503/ jpn.180174. 52. Levinta A, Mukovozov I, Tsoutsoulas C. Use of a gluten-free diet in schizophrenia: a systematic review. Advances in Nutrition. 2018; 9(6): 824–832. doi: 10.1093/advances/nmy056. 53. Kelly DL, Demyanovich HK, Rodriguez KM, et al. Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study. Journal of Psychiatry and Neuroscience. 2019; 44(4): 269–276. doi: 10.1503/ jpn.180174. 54. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. British Journal of Psychiatry. 2004; 184(S47): s102–s105.doi: 10.1192/ bjp.184.47.s102. 55. Aucoin M, LaChance L, Cooley K, Kidd S. Diet and psychosis: a scoping review. Neuropsychobiology. October 2018: 1–23. doi: 10.1159/000493399. 56. Subramaniam M, Mahesh MV, Peh CX, et al. Hazardous alcohol use among patients with schizophrenia and depression. Alcohol. 2017; 65: 63–69. doi: 10.1016/j.alcohol.2017.07.008; Hambrecht M, Häfner H. Do alcohol or drug abuse induce schizophrenia? [на немецком языке]. Nervenarzt. 1996; 67(1): 36–45. 57. Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatrica Scandinavica. 1991; 84(3): 272–276. doi: 10.1111/j.1600-0447.1991.tb03143.x. 58. Messias E, Bienvenu OJ. Suspiciousness and alcohol use disorders in schizophrenia. Journal of Nervous and Mental Disease. 2003; 191(6): 387–390. doi: 10.1097/01. nmd.0000071587. 92959.ba; Pristach CA, Smith CM. Self-reported effects of alcohol use on symptoms of schizophrenia. Psychiatric Services. 1996; 47(4): 421–423. doi: 10.1176/ps.47.4.421. 59. Nesvag R, Frigessi A, Jonsson E, Agartz I. Effects of alcohol consumption and antipsychotic medication on brain morphology in schizophrenia. Schizophrenia Research. 2007; 90 (1–3): 52–61. doi: 10.1016/j.schres.2006.11.008; Smith MJ, Wang L, Cronenwett W, et al. Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia. Schizophrenia Research. 2011; 131(1–3): 174–183. doi: 10.1016/j.schres.2011.05.014. 60. Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders. Archives of General Psychiatry. 2010; 67(2): 146. doi: 10.1001/ archgenpsychiatry.2009.192. 61. Akter K, Gallo DA, Martin SA, et al. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia. Journal of Clinical Pharmacy and Therapeutics. 2011; 37(2): 132–139. doi: 10.1111/ j.1365-2710.2011.01265.x. 62. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review [на французском языке]. Encephale. 2006; 32(2 Pt 1): 244–252. Список литературы 425 63. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Disease Markers. 2006; 22 (1–2): 83–93. doi: 10.1155/2006/248387; Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2007; 33(9): 2187–2199. doi: 10.1038/sj.npp.1301624; Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. European Journal of Clinical Pharmacology. 1992; 43(6): 667–669. doi: 10.1007/ bf02284971. 64. Arroll MA, Wilder L, Neil J. Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutrition Journal. 2014; 13(1). doi: 10.1186/1475-2891-13-91. 65. Farokhnia M, Azarkolah A, Adinehfar F, et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Clinical Neuropharmacology. 2013; 36(6): 185–192. doi: 10.1097/wnf.0000000000000001. 66. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia — a double-blind, randomized, placebo- controlled trial. Biological Psychiatry. 2008; 64(5): 361–368. doi: 10.1016/j.biopsych.2008.03.004. 67. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta (BBA) — General Subjects. 2009; 1790(10): 1149–1160. doi: 10.1016/j.bbagen.2009.07.026. 68. Ratliff JC, Palmese LB, Reutenauer EL, Tek C. An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Clinical Schizophrenia and Related Psychoses. 2015; 8(4): 196–200. doi: 10.3371/csrp.rapa.030113; Sanders LLO, de Souza Menezes CE, Chaves Filho AJM, et al. α-Lipoic acid as adjunctive treatment for schizophrenia. Journal of Clinical Psychopharmacology. 2017; 37(6): 697–701. doi: 10.1097/ jcp.0000000000000800. 69. Seybolt SEJ. Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia? Medical Hypotheses. 2010; 75(6): 572–575. doi: 10.1016/j.mehy.2010.07.034. 70. Arroll MA, Wilder L, Neil J. Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutrition Journal. 2014; 13(1). doi: 10.1186/1475-2891-13-91. 71. Brown HE, Roffman JL. Vitamin supplementation in the treatment of schizophrenia. CNS Drugs. 2014; 28(7): 611–622. doi: 10.1007/ s40263-014-0172-4. 72. Brown AS, Bottiglieri T, Schaefer CA, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Archives of General Psychiatry. 2007; 64(1): 31. doi: 10.1001/ archpsyc.64.1.31. 73. Kemperman RFJ, Veurink M, van der Wal T, et al. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2006; 74(2): 75–85. doi: 10.1016/ j.plefa.2005.11.004. Ума Найду 426 74. Muntjewerff J-W, van der Put N, Eskes T, et al. Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Research. 2003; 121(1): 1–9. doi: 10.1016/ s0165-1781(03)00200-2. 75. Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. American Journal of Psychiatry. 2004; 161(9): 1705–1708. doi: 10.1176/appi.ajp. 161.9.1705. 76. Godfrey PS, Toone BK, Bottiglieri T, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990; 336(8712): 392– 395. doi: 10.1016/0140-6736(90)91942-4. 77. Roffman JL, Lamberti JS, Achtyes E, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013; 70(5): 481. doi: 10.1001/ jamapsychiatry.2013.900. 78. Roffman JL, Petruzzi LJ, Tanner AS, et al. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Molecular Psychiatry. 2017; 23(2): 316–322. doi: 10.1038/mp.2017.41. 79. Ritsner MS, Miodownik C, Ratner Y, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry. 2010;72(1):34–42. doi:10.4088/jcp.09m05324gre; Ota M, Wakabayashi C, Sato N, et al. Effect of l-theanine on glutamatergic function in patients with schizophrenia. Acta Neuropsychiatrica. 2015; 27(5): 291–296. doi: 10.1017/neu.2015.22. 80. Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. Journal of Clinical Psychiatry. 2000; 61(5): 373–377. doi: 10.4088/ jcp.v61n0509; Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metabolic Brain Disease. 2012; 27(2): 113–119. doi: 10.1007/s11011-012-9307-9. |